Analysis of postoperative adjuvant therapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
09 2022
Historique:
received: 07 12 2021
revised: 02 03 2022
accepted: 10 03 2022
pubmed: 1 4 2022
medline: 4 10 2022
entrez: 31 3 2022
Statut: ppublish

Résumé

Gastric-type mucinous carcinoma (GAS) is a novel variant of uterine cervix mucinous carcinoma. GAS is a distinct entity that can be distinguished from typical endocervical adenocarcinoma (UEA). In Japan, postoperative adjuvant therapy for cervical cancer includes not only radiation therapy (RT) or concurrent chemoradiotherapy (CCRT) but also chemotherapy in many cases. However, no previous studies have analyzed adjuvant therapy for GAS. In the present study, we investigated the efficacy of adjuvant therapy for GAS. This was a preplanned secondary analysis of a dataset from previous nationwide, retrospective, observational study. The study population comprised women with stage I-II GAS who underwent surgery. Progression-free survival (PFS) and overall survival (OS) were compared among patients who did and did not receive adjuvant therapy using the Kaplan-Meier method. Data were analyzed for a total of 102 enrolled patients, who were classified as low- (17 patients), intermediate- (37 patients), or high risk (48 patients) based on the risk of postoperative cervical cancer recurrence. In the intermediate-risk group, median survival could not be assessed due to a lack of sufficient events, but the no-adjuvant and RT groups tended to exhibit better prognoses. In contrast, within the high-risk group, patients in the RT subgroup exhibited a trend towards better PFS and OS than those in the CCRT and chemotherapy groups. The prognosis of GAS was confirmed to be poor, even in cases of early-stage cancer and following surgical resection. Chemotherapy strategies, including CCRT as postoperative adjuvant therapy, tend to have a poor prognosis.

Identifiants

pubmed: 35354541
pii: S0748-7983(22)00129-9
doi: 10.1016/j.ejso.2022.03.007
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2039-2044

Informations de copyright

Copyright © 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Shin Nishio (S)

Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan. Electronic address: shinshin@med.kurume-u.ac.jp.

Koji Matsuo (K)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.

Hiroki Nasu (H)

Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.

Kenta Murotani (K)

Biostatistics Center, Graduate School of Medicine, Kurume University, Fukuoka, Japan.

Yoshiki Mikami (Y)

Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan.

Nobuo Yaegashi (N)

Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Toyomi Satoh (T)

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Aikou Okamoto (A)

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.

Mitsuya Ishikawa (M)

Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.

Tsutomu Miyamoto (T)

Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Masaki Mandai (M)

Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Kazuhiro Takehara (K)

Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.

Hideaki Yahata (H)

Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.

Munetaka Takekuma (M)

Department of Gynecologic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

Kimio Ushijima (K)

Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH